Empagliflozin does not decrease risk of hospitalization or death after myocardial infarction
1. In this randomized controlled trial, empagliflozin was not shown to decrease the risk of hospitalization for heart failure or ...
Tag: empagliflozin
#VisualAbstract: Empagliflozin does not significantly reduce the risk of heart failure or death in patients after acute myocardial infarction
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Empagliflozin Shows Promise As An Adjunct To Selective Serotonin Reuptake Inhibitors In Reducing Symptom Severity In Major Depressive Disorder
1. Combination therapy of empagliflozin and citalopram reduced symptom severity in patients with major depressive disorder. 2. This average reduction ...
Empagliflozin use is associated with slower progression of chronic kidney disease
1. Empagliflozin led to a lower risk of kidney disease progression in patients with chronic kidney disease (CKD) as compared ...
#VisualAbstract: Treatment with empagliflozin reduced progression of chronic kidney disease
Click here to read this study in NEJM
SGLT-2 inhibitors provide morbidity and mortality benefits for patients with heart failure
1. SGLT-2 inhibitors reduced time to first hospitalization and cardiovascular death among patients with preserved, mildly reduced, and reduced ejection ...
Sodium glucose cotransporter-2 inhibitor use associated with increased risk of diabetic ketoacidosis
1. The use of sodium-glucose cotransporter-2 (SGLT-2i) increased study participants’ risk of diabetic ketoacidosis (DKA) hospital presentations when compared to ...